Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations

References

• International Diabetes Federation IDF Diabetes Atlas 5th ed Brussels, Belgium International Diabetes Federation 2011 Available from: http://www.idf.org/diabetesatlas Accessed May 16, 2012
   Google Scholar
• The DECODE Study Group Glucose tolerance and cardiovascular mortality Arch Intern Med 2001 161 397 404 11176766
   PubMed Web of Science ®Google Scholar
• Bischoff H Effect of acarbose on diabetic late complications and risk factors – new animal experimental results Akt Endokr Stoffw 1991 12 25 32
   Google Scholar
• Elsenhans B Caspary WF Absorption of carbohydrates Caspary WF Structure and Function of the Small Intestine Amsterdam, The Netherlands Excerpta Medica 1987
   Google Scholar
• Puls W Pharmacology of glucosidase inhibitors Kuhlmann J Puls W Handbook of Experimental Pharmacology: Oral Antidiabetics 119 Berlin, Germany Springer 1996
   Google Scholar
• Bischoff H Alpha-glucosidase inhibition, a new therapeutic principle in the management of diabetes mellitus Schwartz CJ Born GVR New Horizons in Diabetes Mellitus and Cardiovascular Disease London, UK Current Science 1995
   Google Scholar
• Rosak C Mertes G Effects of acarbose on proinsulin and insulin secretion and their potential significance for the intermediary metabolism and cardiovascular system Curr Diabetes Rev 2009 5 157 164 19689250
   PubMedGoogle Scholar
• Alessema M Dekker JM Nijpels G Stehouwer CDA Bouter LM Heine RJ Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study Diabetes Care 2005 28 860 865 15793186
   PubMed Web of Science ®Google Scholar
• Qualmann C Nauck MA Holst JJ Orskov C Creutzfeldt W Glucagon-like peptide 1 (GLP-1) [17–36 amide] secretion in response to luminal sucrose from the upper and lower gut: a study using alpha-glucosidase inhibition (acarbose) Scand J Gastroenterol 1995 30 892 896 8578189
   PubMed Web of Science ®Google Scholar
• Göke B Fuder H Wieckhorst G Voglibose is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve Digestion 1995 56 493 501 8536820
   PubMed Web of Science ®Google Scholar
• Hanefeld M Temelkowa-Kurktschiev T The postprandial state and the risk of atherosclerosis Diab Med 1997 14 S6 S11
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E Ferrara A Isolated postprandial hyperglycemia and the risk of fatal cardiovascular disease in older woman and men. The Rancho Bernardo Study Diabetes 1998 21 1236 1240
   Web of Science ®Google Scholar
• de Vegt F Dekker JM Ruhè HG Stehouwer CDA Nijpels GBLM Heine RJ Hyperglycemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study Diabetologia 1999 42 926 931 10491751
   PubMed Web of Science ®Google Scholar
• Giugliano D Marfella R Coppola L Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia Circulation 1997 95 1783 1790 9107164
   PubMed Web of Science ®Google Scholar
• Kawano H Motoyama T Hirashima O Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery J Am Coll Cardiol 1999 34 146 154 10400004
   PubMed Web of Science ®Google Scholar
• Ceriello A Falleti E Motz E Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress Horm Metab Res 1998 30 146 149 9566857
   PubMed Web of Science ®Google Scholar
• Marfella R Esposito K Giunta R Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia Circulation 2000 101 2247 2251 10811590
   PubMed Web of Science ®Google Scholar
• Esposito K Nappo F Marfella R Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress Circulation 2002 106 2067 2072 12379575
   PubMed Web of Science ®Google Scholar
• Festa A D’Agostino RJr Tracy RP Haffner SM C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjects; the Insulin Resistance Atherosclerosis Study Diab Med 2002 19 939 943
   PubMed Web of Science ®Google Scholar
• Shimabukuro M Higa N Chinen I Yamakawa K Takasu N Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study J Clin Endocrinol Metab 2006 91 837 842 16368744
   PubMed Web of Science ®Google Scholar
• Wascher TC Schmoelzer I Wiegratz A Reduction of postchallenge hyperglycemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance Eur J Clin Invest 2005 35 551 557 16128861
   PubMed Web of Science ®Google Scholar
• Kato T Inoue T Node K Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study Cardiovasc Diabetol 2010 9 12 16 20334663
   PubMed Web of Science ®Google Scholar
• Hanefeld M Chiasson JL Koehler C Henkel E Schaper F Temelkova-Kurktschiev T Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance Stroke 2004 35 1073 1078 15073402
   PubMed Web of Science ®Google Scholar
• Rosenthal JH Mauersberger H Effects on blood pressure of the alpha-glucosidase- inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus Clin Drug Investig 2002 22 695 701
   Web of Science ®Google Scholar
• Hanefeld M Catagay M Petrowitsch T Neuser D Petzinna D Rupp M Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies Eur Heart J 2004 25 10 16 14683737
   PubMed Web of Science ®Google Scholar
• Wang X Lu J Pan C Comparison of serum C-reactive protein level in different glucose tolerant subjects and the change in serum CRP level in IGT subjects with acarbose Chin J Endocrinol Metab 2003 19 254 256
   Google Scholar
• Rudofski G Reismann P Schiekofer S Reduction of postprandial hyperglycemia in patients with Type 2 diabetes reduces NF-kappaB activation in PBMCs Horm Metab Res 2004 36 630 638 15486815
   PubMed Web of Science ®Google Scholar
• Baron AD Eckel RH Schmeiser L Kolterman OG The effect of short-term alpha-glucosidase inhibition on carbohydrate and lipid metabolism in type II diabetics Metabolism 1987 36 409 415 3553848
   PubMed Web of Science ®Google Scholar
• Kado S Murakami T Aoki A Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus Diab Res Clin Pract 1998 41 49 55
   PubMed Web of Science ®Google Scholar
• Malaguarnera M Giugno I Ruello P Rizzo M Motto M Mazzoleni G Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridemias Br J Clin Pharmacol 1999 48 605 609 10583032
   PubMed Web of Science ®Google Scholar
• Ogawa S Takeuchi K Ito S Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes Diab Obes Metab 2004 6 384 390
   PubMed Web of Science ®Google Scholar
• Tushuizen ME Diamant M Heine RJ Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes Postgrad Med J 2005 81 1 6 15640422
   PubMed Web of Science ®Google Scholar
• Ceriello A Taboga C Tonutti L Post-meal coagulation activation in diabetes mellitus: the effect of acarbose Diabetologia 1996 39 469 473 8777997
   PubMed Web of Science ®Google Scholar
• Tschoepe D Decreased fibrinogen by treatment with the alpha-glucosidase inhibitor acarbose Diabetes 2004 53 Suppl 2 A189
   Google Scholar
• Shinoda Y Inoue I Nakano T Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance Metabolism 2006 55 935 939 16784967
   PubMed Web of Science ®Google Scholar
• Rathmann W Giani G Mielck A Cardiovascular risk factors in newly diagnosed abnormal glucose tolerance: comparison of 1997 ADA and WHO criteria Diabetologia 1999 42 1268 1269 10525673
   PubMed Web of Science ®Google Scholar
• Coutinho M Gerstein HC Wang Y Yussuf S The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years Diabetes Care 1999 22 233 240 10333939
   PubMed Web of Science ®Google Scholar
• Laakso M Hyperglycemia and cardiovascular disease in type 2 diabetes Diabetes 1999 48 937 942 10331395
   PubMed Web of Science ®Google Scholar
• Chiasson JL Josse RG Gomis R Hanefeld M Karasik A Laakso M Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial Lancet 2002 359 2072 2077 12086760
   PubMed Web of Science ®Google Scholar
• Chiasson J-L Josse RG Gomis R Hanefeld M Karasik A Laakso M Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial JAMA 2003 290 486 494 12876091
   PubMed Web of Science ®Google Scholar
• Hanefeld M Pistrosch F Koehler C Chiasson JL Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension: a post-hoc analysis of the STOP-NIDDM trial J Hypertens 2012 30 1440 1443 22573126
   PubMed Web of Science ®Google Scholar
• Acarbose Cardiovascular Evaluation (ACE study) Available from: http://www.dtu.ox.ac.uk/ace/ Accessed June 19, 2012
   Google Scholar
• Coniff RF Shapiro JA Seaton TB Bray GA Multicenter, placebo-controlled trial comparing acarbose (Bay g 5421) with placebo, tolbutamide and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus Am J Med 1995 98 443 451 7733122
   PubMed Web of Science ®Google Scholar
• Rosak C Haupt E Walter T Werner J The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia Diabetes Nutr Metab 2002 15 143 151 12173728
   PubMedGoogle Scholar
• Phung OJ Scholle JM Talwar M Coleman CI Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes JAMA 2010 303 1410 1418 20388897
   PubMed Web of Science ®Google Scholar
• Lin SD Wang JS Hsu SR The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data J Diabetes Complications 2011 25 332 338 21813293
   PubMed Web of Science ®Google Scholar
• Tschöpe D Bramlage P Binz C Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients – an analysis of the DiaRegis registry Cardiovasc Diabetol 2011 10 66 21756359
   PubMed Web of Science ®Google Scholar
• van de Laar FA Lucassen PL Akkermans LP van de Lisdonk EH Rutten GE van Weel C Alpha-glucosidase inhibitors for patients with type 2 diabetes. Results from a Cochrane systematic review and metaanalysis Diabetes Care 2005 28 154 163 15616251
   PubMed Web of Science ®Google Scholar
• Bolen S Feldmann L Vassy J Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus Ann Intern Med 2007 147 386 399 17638715
   PubMed Web of Science ®Google Scholar
• Schnell O Mertes G Standl E on behalf of the Acarbose-Insulin Combination Study Group Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy Diabetes Obes Metab 2007 9 853 888 17924867
   PubMed Web of Science ®Google Scholar
• Li C Hung YJ Quamruddin K Aziz MFA Stein H Schmidt B International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus Diab Res Clin Pract 2011 92 57 64
   PubMed Web of Science ®Google Scholar
• Willms B Ruge D Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study Diabet Med 1999 16 755 761 10510952
   PubMed Web of Science ®Google Scholar
• Pan C Yang W Barona JP Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial Diabet Med 2008 25 435 441 18341596
   PubMed Web of Science ®Google Scholar
• Home PD Pocock SJ Beck-Nielsen H Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 2009 373 2125 2135 19501900
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 1998 352 854 865 9742977
   PubMed Web of Science ®Google Scholar
• Holman RR Turner RC Cull CA on behalf of the UKPDS Study Group A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UKPDS 44) Diabetes Care 1999 22 960 964 10372249
   PubMed Web of Science ®Google Scholar
• Fischer S Hanefeld M Spengler M Boehme K Temelkowa-Kurktschiev T European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus Acta Diabetol 1998 35 34 40 9625287
   PubMed Web of Science ®Google Scholar
• Hasche H Mertes G Bruns C Effects of acarbose treatment in type 2 diabetic patients under dietary training: a multicenter, double-blind, placebo-controlled, 2-year study Diabetes Nutr Metab 1999 12 277 285 10782754
   PubMedGoogle Scholar
• Mertes G Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study Diabetes Res Clin Pract 2001 52 193 204 11323089
   PubMed Web of Science ®Google Scholar
• Brauer PM Slavin JL Marlett JA Apparent digestibility of neutral detergent fiber in elderly and young adults Am J Clin Nutr 1981 34 1061 1070 6263073
   PubMed Web of Science ®Google Scholar
• Bowman B Rosenberg IH Digestive function and aging Hum Nutr Clin Nutr 1983 37C 75 89 6345479
   PubMedGoogle Scholar
• Welsh JD Poley JR Bhatia M Stevenson DE Intestinal disaccharidase activities in relation to age, race and mucosal damage Gastroenterology 1978 75 847 855 100368
   PubMed Web of Science ®Google Scholar
• Buse J Hart K Minasi LA on behalf of the PROTECT Study Group The PROTECT study: Final results of a large multicenter postmarketing study in patients with type 2 diabetes Clin Ther 1998 20 257 269 9589817
   PubMed Web of Science ®Google Scholar
• Spengler M Schmitz H Landen H Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus – a postmarketing surveillance study Clin Drug Investig 2005 25 651 659
   PubMed Web of Science ®Google Scholar
• Pan CY Landen H Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with IGT in China Clin Drug Investig 2007 27 397 405
   PubMed Web of Science ®Google Scholar
• Santeusiano F Ventura MM Contadini S Efficacy and safety of two different dosages of acarbose in non-insulin dependent diabetic patients treated by diet alone Diabetes Nutr Metab 1993 6 147 154
   Google Scholar
• Radziuk J Kemmer F Morishima T Berchtold P Vranic M The effects of an alpha-glucosidase hydrolase inhibitor on glycemia and the absorption of sucrose in man determined using a tracer method Diabetes 1984 33 207 213 6365657
   PubMed Web of Science ®Google Scholar
• May C Wirksamkeit und Verträglichkeit von einschleichend dosierter Acarbose bei Patienten mit nichtinsulinpflichtigem Diabetes mellitus unter Sulfonylharnstofftherapie Diabetes Stoffwechsel 1995 4 3 8 German
   Google Scholar
• Creutzfeldt W Fölsch UR Elsenhaus B Ballmann M Conlon M Adaptation of the small intestine to induced maldigestion Scand J Gastroenterol 1985 20 45 53
   Web of Science ®Google Scholar
• Koytchev R Richter W Erkent U Influence of acarbose on blood glucose and breath hydrogen after carbohydrate load with sucrose or starch Arzneimittelforschung 2009 59 557 563 20066964
   PubMed Web of Science ®Google Scholar
• Sherifali D Nerenberg K Pullenayegum E Cheng JE Gerstein HC The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis Diabetes Care 2010 33 1859 1864 20484130
   PubMed Web of Science ®Google Scholar
• Ashcroft FM Mechanism of the glycemic effects of sulfonylureas Horm Metab Res 1996 28 456 463 8911983
   PubMed Web of Science ®Google Scholar
• Panten U Schwanstecher M Schwanstecher C Sulfonylurea receptors and mechanism of sulfonylurea action Exp Clin Endocrinol Diabetes 1996 104 1 9 8750563
   PubMed Web of Science ®Google Scholar
• Bijlstra PJ Luttermann JA Russel FGM Thien T Smits P Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans Diabetologia 1996 39 1083 1090 8877293
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group Intensive blood- glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998 352 837 853 9742976
   PubMed Web of Science ®Google Scholar
• Giovannucci E Harlan DM Archer MC Diabetes and cancer: A consensus report Diabetes Care 2010 33 1674 1685 20587728
   PubMed Web of Science ®Google Scholar
• Guay DRP Repaglinide, a novel short-acting hypoglycemic agent for type 2 diabetes mellitus Pharmacotherapy 1998 18 1195 1204 9855316
   PubMed Web of Science ®Google Scholar
• Marbury T Huang WC Strange P Lobovitz H Repaglinide versus glyburide: a one year comparison trial Diab Res Clin Pract 1999 43 155 165
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT Metformin Diabetes Care 1995 18 1078 1092 7555549
   PubMed Web of Science ®Google Scholar
• Bailey CJ Turner RC Metformin N Engl J Med 1996 334 574 579 8569826
   PubMed Web of Science ®Google Scholar
• Li CL Pan CY Lu JM Effect of metformin on patients with impaired glucose tolerance Diabet Med 1999 16 477 481 10391395
   PubMed Web of Science ®Google Scholar
• Yang W Lin L Qi J The preventive effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicenter prospective study Chin J Endocrinol Metab 2001 17 131 136
   Google Scholar
• Nissen SE Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 2007 356 2457 2471 17517853
   PubMed Web of Science ®Google Scholar
• Graham DJ Ouellet-Hellstrom R MaCurdy TE Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone JAMA 2010 304 411 418 20584880
   PubMed Web of Science ®Google Scholar
• Wertz DA Chang CL Sarawate CA Willey VJ Cziraky MJ Bohn RL Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population Circ Cardiovasc Qual Outcomes 2010 3 538 545 20736441
   PubMed Web of Science ®Google Scholar
• Loke YK Kwok CS Singh S Comparative cardiovascular effects of thiazolidinediones: systematic review and metaanalysis of observational studies BMJ 2011 342 d1309 21415101
   PubMed Web of Science ®Google Scholar
• Kahn SE Zinman B Lachin JM Rosiglitazone-associated fractures in type 2 diabetes Diabetes Care 2008 31 845 851 18223031
   PubMed Web of Science ®Google Scholar
• Dormuth CR Carney G Carleton B Bassett K Wright JM Thiazolid-indiones and fractures in men and women Arch Intern Med 2009 169 1395 1402 19667303
   PubMed Web of Science ®Google Scholar
• Idris I Warren G Donnelly R Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes Arch Intern Med 6 11 2012 [Epub ahead of print.]
   Google Scholar
• Piccinni C Motola D Marchesini G Poluzzi E Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting Diabetes Care 2011 34 1369 1371 21515844
   PubMed Web of Science ®Google Scholar
• Kahn SE Haffner SM Heise MA Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 2008 355 2427 2443 17145742
   PubMed Web of Science ®Google Scholar
• Ryan KK Li B Grayson BE Matter EK Woods SC Seeeley RJ A role for central nervous system PPAR-γ in the regulation of energy balance Nat Med 2011 17 623 626 21532595
   PubMed Web of Science ®Google Scholar
• Cure P Pileggi A Alejandro R Exenatide and adverse events N Engl J Med 2008 358 1969 1970 18450614
   PubMed Web of Science ®Google Scholar
• Amori RE Lau J Pittas AG Efficacy and safety of incretin therapy in type 2 diabetes. Systematic review and metaanalysis JAMA 2007 298 194 206 17622601
   PubMed Web of Science ®Google Scholar
• Williams-Herman D Engel SS Round E Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes BMC Endocr Disord 2010 10 7 11 20412573
   PubMed Web of Science ®Google Scholar
• Richter B Bandeira-Echtler E Bergerhoff K Lerch C Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes Vasc Health Risk Manag 2008 4 753 768 19065993
   PubMedGoogle Scholar
• Tripathy NR Basha S Jain R Shetty S Ramachandran A Exenatide and acute pancreatitis J Assoc Physicians India 2008 56 987 988 19322980
   PubMedGoogle Scholar
• Elashoff M Matveyenko AV Gier B Elashoff R Butler PC Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide- 1-based therapies Gastroenterology 2011 141 150 156 21334333
   PubMed Web of Science ®Google Scholar
• Drucker DJ Sherman SI Gorelick FS Bergenstal RM Sherwin RS Buse JB Incretin-based therapies for the treatment of type 2 diabetes: Evaluation of the risks and benefits Diabetes Care 2010 33 428 433 20103558
   PubMed Web of Science ®Google Scholar
• Salvatore T Giugliano D Pharmacokinetic-pharmacodynamic relationships of acarbose Clin Pharmacokinet 1996 30 94 106 8906894
   PubMed Web of Science ®Google Scholar
• Ahr HJ Krause HP Siefert HM Steinke W Weber H Pharmacokinetics of acarbose, Part II: Distribution to and elimination from tissues and organs following single or repeated administration of [14C] acarbose to rats, dogs and man Arzneimittelforschung 1989 39 1261 1267 2610718
   PubMed Web of Science ®Google Scholar
• Coniff RF Krol A Acarbose: a review of US clinical experience Clin Ther 1997 19 16 26 9083705
   PubMed Web of Science ®Google Scholar
• Lebovitz HE Alpha-glucosidase-inhibitors as agents in the treatment of type 2 diabetes Diabetes Reviews 1998 6 132 145
   Google Scholar
• Haupt E Hillebrand I Pfeiffer H Effectiveness and tolerability of the alpha-glucosidase-inhibitor acarbose in NIDDM patients with elevated liver enzyme activity Creutzfeldt W Acarbose for the Treatment of Diabetes Mellitus Berlin, Germany Springer Verlag 1988
   Google Scholar
• Zillikens MC Swart GR van den Berg JWO Wilson JHP Effects of the glucosidase-inhibitor acarbose in patients with liver cirrhosis Aliment Pharmacol Ther 1989 3 453 459 2518858
   PubMed Web of Science ®Google Scholar
• Kihara Y Ogami Y Tabaru A Unoki H Otsuki M Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase-inhibitor, acarbose Gastroenterology 1997 6 777 782
   Google Scholar
• Rao AD Reynolds K Kuhadiya N Fonsera VA Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis Diabetes Care 2008 31 1672 1678 18458139
   PubMed Web of Science ®Google Scholar
• Rosak C Nitzsche G Konig P Hofmann U The effect of timing and the administration of acarbose on postprandial hyperglycemia Diab Med 1995 12 979 984
   PubMed Web of Science ®Google Scholar